Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2022

View Archived Issues

CYSLTR1 blockade as a strategy to prevent breast cancer progression

Researchers identify DAW1 gene variants linked to motile ciliopathy

Design of a novel TAM inhibitor as a potential cancer therapy

Orion Corporation patents new CYP11A1 inhibitors

Wellstat Therapeutics divulges novel uridine derivatives

Eternity Bioscience synthesizes IRAK4 inhibitors

Vilnius University presents new carbonic anhydrase IX ligands

KalVista Pharmaceuticals patents FXIIa inhibitors

[68Ga]NOTA-cc90 demonstrates imaging of LAG-3 expression on tumor-infiltrating lymphocytes

FABP5 inhibitor ART26.12 shows promise for chemotherapy-induced pain

Ono and Fate Therapeutics expand drug discovery collaboration to include CAR-NK cell therapy

FDA clears IND for MALT1 inhibitor SGR-1505 for B-cell lymphomas

BiomX collaborates with Boehringer Ingelheim on biomarkers for IBD-associated pathogenic bacterium

Palleon and Henlius collaborate to codevelop bifunctional sialidase therapeutics

Series B financing at MiroBio funds development of checkpoint agonists to treat autoimmune diseases

miR-135b discriminates tongue cancer from noncancerous tissue

PDX models of radiation-resistant pediatric high-grade glioma show sensitivity to MAPK inhibition

Scorpion selects Exon 20 mutant EGFR inhibitor STX-721 as development candidate

Myelin-forming cells change in multiple brain diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.